Skip to content

Bioequivalence of a Diabetes Specific Tube Feed

Bioequivalence of a Diabetes Specific Tube Feed

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05453838
Acronym
EQUIDIA
Enrollment
22
Registered
2022-07-12
Start date
2022-09-07
Completion date
2022-11-29
Last updated
2025-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postprandial Glucose Response

Brief summary

Nutricia has a range of nutritionally complete tube feeds on the market including some specific for diabetes patients. A new product is currently under development. The aim of the present study is to assess whether the postprandial glucose response of the new product is equivalent to the postprandial glucose response of an original product. In addition, the Glycaemic Index (GI) and Glycaemic Load (GL) of the adapted product will be determined. The study will have a crossover design with healthy volunteers taking one serving of both products in a randomized order. To determine GI and GL of the adapted product subjects will also receive a reference product. Subjects will visit the study site six times: one screening visit, three study visits to measure the glucose response to the reference product and two study visits to measure the glucose response to the test and control product.

Interventions

DIETARY_SUPPLEMENToral intake of one serving of the original and new product

1\) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product

Sponsors

Nutricia Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)

Masking description

Single blind

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age ≥ 18 and ≤ 65 years 2. Body Mass Index (BMI) ≥ 18.5 and ≤ 27.0 kg/m2 3. Written informed consent 4. Willingness and ability to comply with the protocol 5. Judged by the Investigator to be in good health

Exclusion criteria

1. Known Diabetes Mellitus type I or type II, rebound hypoglycaemia and/or any other medical condition that interferes with glucose metabolism 2. Any use of anticoagulants, systemic steroids, protease inhibitors or antipsychotics and/or any medication known to affect glucose tolerance and/or to influence digestion and absorption of nutrients within 1 week of screening, in opinion of the Investigator 3. Any known disease which influences digestion and absorption of nutrients within 1 week of screening (in the opinion of the Investigator) 4. Allergy to soy and/or any other known relevant food allergy or intolerance in opinion of the Investigator 5. Adherence to a strict vegan diet 6. Adherence to a weight loss program 7. Picky/fussy eater (being very selective about what to eat) or eating disorder 8. Known pregnancy and/or lactation 9. Current smoking or stopped smoking for \< 1 month prior to screening (except for incidental smoking of ≤ 3 cigarettes/cigars/pipes per week on average in the last month) 10. Average alcohol use of \> 21 glasses per week for men or \> 14 glasses per week for women (on average during the last 6 months) 11. Drug or medicine abuse in opinion of the Investigator 12. Any known bleeding disorder 13. Active participation in any other clinical study with investigational or marketed products concomitantly or within 4 weeks before study visit 1, in the opinion of the Investigator 14. Major medical or surgical event requiring hospitalization within the preceding 3 months and/or scheduled in the period of study participation relevant in the opinion of the Investigator 15. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements 16. Employees of Nutricia Research and/or family members or relatives of employees

Design outcomes

Primary

MeasureTime frameDescription
Blood glucose - Product A versus Product B120 minutesBlood glucose iAUC0-120 \[mmol/L\*min\] \[mmol/L\]

Secondary

MeasureTime frameDescription
GI new product120 minutesGI = blood glucose iAUC0-120 \[mmol/L\] of new product / mean blood glucose iAUC0-120 \[mmol/L\] of reference product
GL new product120 minutesGL = GI \* available carbohydrate/given amount of carbohydrate

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026